Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) Drug Overview 2018: A Fixed-Dose Combination of an Inhaled Corticosteroid and a Long-Acting Beta 2 Agonist - ResearchAndMarkets.com

The "Drug Overview: Advair" report has been added to ResearchAndMarkets.com's offering.

Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose combination of an inhaled corticosteroid (fluticasone propionate) and a long-acting beta 2 agonist (salmeterol). The drug has anti-inflammatory and bronchodilatory effects on patients with asthma. It is administered twice daily through a dry powder inhaler device called Advair Diskus, or a pressurized metered-dose inhaler device known as Advair hydrofluoroalkane (HFA).

Key Topics Covered:

Product Profiles

Advair: Asthma

Advair: Chronic obstructive pulmonary disease (COPD)

List of Figures

Figure 1: Advair for asthma - SWOT analysis

Figure 2: Drug assessment summary of Advair in asthma

Figure 3: Drug assessment summary of Advair in asthma

Figure 4: Advair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

Figure 5: Advair for COPD - SWOT analysis

Figure 6: Drug assessment summary of Advair for COPD

Figure 7: Drug assessment summary of Advair for COPD

List of Tables

Table 1: Advair drug profile

Table 2: Advair Diskus pivotal trial data in asthma

Table 3: Advair HFA pivotal trial data in asthma

Table 4: Advair late-phase trial data in asthma

Table 5: Advair sales for asthma across the US, Japan, and five major EU markets, by country M, 2017-26

Table 6: Advair drug profile

Table 7: Overview of pivotal trial data for Advair Diskus in COPD

For more information about this report visit https://www.researchandmarkets.com/research/z8gsws/advair?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180514006225/en/